Invention Grant
US08946224B2 Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions
有权
用于药物和药物组合物的取代的[1,2,4]三唑并[4,3-A]吡嗪
- Patent Title: Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions
- Patent Title (中): 用于药物和药物组合物的取代的[1,2,4]三唑并[4,3-A]吡嗪
-
Application No.: US13883713Application Date: 2011-11-11
-
Publication No.: US08946224B2Publication Date: 2015-02-03
- Inventor: Mark Craighead , Ronald Palin , Neil Murray , Derek Lindsay
- Applicant: Mark Craighead , Ronald Palin , Neil Murray , Derek Lindsay
- Applicant Address: GB Liverpool
- Assignee: Redx Pharma Limited
- Current Assignee: Redx Pharma Limited
- Current Assignee Address: GB Liverpool
- Agency: Morgan, Lewis & Bockius LLP
- Priority: GB1019078.3 20101111; GB1019527.9 20101118
- International Application: PCT/GB2011/052211 WO 20111111
- International Announcement: WO2012/063085 WO 20120518
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D487/04 ; C07D498/06 ; C07D413/12 ; C07C63/64 ; C07D213/60 ; C07C217/58 ; C07D403/06 ; C07C69/12 ; C07C235/16 ; C07D257/04 ; C07D313/04 ; C07D407/06 ; C07C43/205 ; C07C215/46 ; C07C255/25 ; C07D205/08 ; C07D281/06 ; C07D417/06 ; C07D413/04 ; C07D401/04 ; C07C63/66 ; C07D499/88 ; C07D401/12 ; C07D519/00 ; C07D209/18 ; C07D307/00 ; C07D501/00 ; C07C233/22 ; C07D473/00 ; C07H19/052 ; C07C251/40 ; C07D403/12 ; C07D513/06 ; C07C251/54 ; C07C257/14 ; C07C251/48 ; C07C57/00 ; C07C233/36 ; C07H19/173 ; C07D411/10 ; C07C229/18 ; C07D295/02 ; C07H19/06 ; C07C235/28 ; C07D233/54 ; C07J5/00 ; C07D471/04 ; C07D241/04 ; C07D235/16 ; C07D277/40 ; C07D417/12 ; C07D309/32 ; C07C237/20 ; C07C251/58 ; C07D401/14 ; C07D491/04
![Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions](/abs-image/US/2015/02/03/US08946224B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. Exemplary derivatives have the formula
Public/Granted literature
- US20130225594A1 DRUG DERIVATIVES Public/Granted day:2013-08-29
Information query
IPC分类: